Skip to content

Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia

Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia: a Cluster Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03992313
Acronym
Cam-C
Enrollment
7692
Registered
2019-06-20
Start date
2022-04-21
Completion date
2023-09-23
Last updated
2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Testing

Brief summary

Objectives Principal objective: to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population aged more than 40 years old in Cambodia Secondary objectives * To compare the HCV antibody testing uptake between the 2 arms for the eligible population * To compare the active case detection rate between the 2 arms for the eligible population * To compare the linkage to care between the 2 arms for those with active infection * To compare the cost-effectiveness of the two strategies * To evaluate the treatment uptake * To evaluate the effectiveness and safety of a 12-week dual-therapy of direct-acting antiviral (DAA) treatment

Detailed description

Methodology: two-arms cluster-randomized controlled trial. Clusters are defined as a group of 50 households Expected enrolment : 8000 patients in 160 clusters, 80 villages in each of the 2 provinces (Kompong Cham and Siem Reap) Intervention Arm 1: Facility-based testing intervention A team of community Health Workers (CHWs) will prepare a schedule to visit the selected villages and provide mass information on the possibility to be tested in health centers for HCV infection. Information will be provided using information sheet and a dedicated leaflet. If the participant agrees to participate, the signed consent form will be collected at this step. HCV testing will be done in one of the referrals health centers. HCV screening will be done using the SD Bioline HCV RDT on a finger stick capillary whole blood. Results will be available in 15 minutes. In case of positive HCV RDT, an immediate blood sample collection will be done in health center and sent to Provincial Hospital to perform HCV RNA using GenXpert viral load assay on plasma. Results will be sent back to the health center and nurses will be in charge to give result to the participant and to refer to care in case of active infection Arm 2: Community-based testing intervention After a dedicated training, CHWs will do the SD Bioline HCV RDT on a finger stick capillary whole blood directly in the household of participant. Information will be provided by the CHW using information sheet and a dedicated leaflet. If the participant agrees to participate, the signed consent form will be collected at this step before any RDT collection. In case of structural or societal barriers for household testing, it will be possible to provide testing in a specific location in the village. The onsite visits will be planned with the head of village who will be in charge to inform the population about the study. In case of absence of participant during the first visit, a second visit will be scheduled. In absence of participant during the second visit, no additional visit will be planned. In case of positive HCV RDT, 5 blood spots will be collected immediately on DBS, dried at ambient temperature and put in an individual plastic bag with the ID number and sent to Phnom Penh (Rodolphe Merieux laboratory) for HCV RNA extraction and amplification (Omunis). Results will be sent back to the referral health center and nurses will be in charge to give result to the participant and to refer to care in case of active infection. Treatment phase For positive HCV RNA, a consultation in the Provincial Hospital will be planned. The Baseline assessment will include questionnaires (risk behaviours and socio-economic status), clinical exam, blood sampling and liver ultrasound. Symptomatic cirrhotic patients will be referred to a National Hospital in Phnom Penh to a hepatology department. For the others patients, DAA treatment using sofosbuvir and daclatasvir combination for 12 weeks (Cambodian Essential Medicine List 2018) will be proposed, after checking the result of creatinine and the possible drug-drug interactions.

Interventions

OTHERCommunity-based HCV rapid test

HCV rapid tests will be done in the village

OTHERFacility-based HCV rapid test

HCV rapid tests will be done in the health center

OTHERPlasmatic HCV viral load

HCV viral load will be done in provincial hospital on plasma using GenXpert

OTHERDBS HCV viral load

HCV viral load will be done in Phnom Penh by DBS using Omunis kit

Sponsors

University of Health Sciences, Phnom Penh, Cambodia
CollaboratorUNKNOWN
Hopital Paul Brousse
CollaboratorOTHER
Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Fondation Mérieux
CollaboratorOTHER
University of Marseille
CollaboratorOTHER
SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD)
CollaboratorUNKNOWN
ANRS, Emerging Infectious Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All persons aged more than 40 years old * Residing in the study area * Informed consent obtained with oral information given and explained and the consent form signed by the participant and the nurse hired by the study at the latest the time of the RDT realization

Exclusion criteria

* Known positive HCV status with previous HCV treatment * Severe disease present at inclusion involving life threatening * Concurrent participation in any other clinical study without written agreement of the two study teams

Design outcomes

Primary

MeasureTime frameDescription
Combined-testing uptake12 monthsCombined-testing uptake defined as the number of persons tested for HCV RDT AND HCV RNA and aware of their status among the total number of persons eligible residing in the region where the intervention takes place

Secondary

MeasureTime frameDescription
Active case detection rate12 monthsdefined as the number of persons with HCV active infection (positive HCV Ab and positive HCV RNA) and results given and explained among the total number of persons eligible residing in the region where the intervention takes place (measured and compared between the 2 arms)
Linkage to care12 monthsthe number of persons with at least one consultation in the Provincial Hospital among the estimated total number of persons with active infection residing in the region where the intervention takes place (measured and compared between the 2 arms)
HCV antibody testing uptake12 monthsHCV antibody testing uptake defined as the number of persons tested for HCV RDT and aware of their status among the total number of persons eligible residing in the region where the intervention takes place

Other

MeasureTime frameDescription
Treatment failure18 monthsProportion of patients with treatment failure defined as absence of SVR12 or missing HCV-RNA at 12 weeks post-treatment (PT12) due to treatment discontinuation for AEs or death (measured for the total population and not compared)
Treatment uptake18 monthsthe number of people initiating HCV treatment among the total number of persons with active infection linked to care (measured for the total population and not compared)
Liver-related morbidity and mortality18 monthsProportion of patients with decompensated cirrhosis, HCC (measured for the total population and not compared)
Sustained virologic response 1218 monthsProportion of patients with sustained virologic response 12 weeks after discontinuation of treatment (SVR12) (measured for the total population and not compared)

Countries

Cambodia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026